Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2021 3
2024 2
2025 1
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Metformin and Aging: A Review.
Glossmann HH, Lutz OMD. Glossmann HH, et al. Gerontology. 2019;65(6):581-590. doi: 10.1159/000502257. Epub 2019 Sep 13. Gerontology. 2019. PMID: 31522175 Review.
As one of the metformin trials has "frailty" as its endpoint, similar to a trial with a plant-derived senolytic, the latter class of novel anti-aging drugs is briefly discussed. Concerns exist not only for vitamin B12 and B6 deficiencies, but also about whether there are a …
As one of the metformin trials has "frailty" as its endpoint, similar to a trial with a plant-derived senolytic, the latter class of …
Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era.
Verdoorn BP, Evans TK, Hanson GJ, Zhu Y, Langhi Prata LGP, Pignolo RJ, Atkinson EJ, Wissler-Gerdes EO, Kuchel GA, Mannick JB, Kritchevsky SB, Khosla S, Rizza SA, Walston JD, Musi N, Lipsitz LA, Kiel DP, Yung R, LeBrasseur NK, Singh RJ, McCarthy T, Puskarich MA, Niedernhofer LJ, Robbins PD, Sorenson M, Tchkonia T, Kirkland JL. Verdoorn BP, et al. J Am Geriatr Soc. 2021 Nov;69(11):3023-3033. doi: 10.1111/jgs.17416. Epub 2021 Aug 20. J Am Geriatr Soc. 2021. PMID: 34375437 Free PMC article.
A clinical trial is underway to test if senolytics decrease SARS-CoV-2 progression and morbidity in hospitalized older adults. We describe here a National Institutes of Health-funded, multicenter, placebo-controlled clinical trial of Fisetin …
A clinical trial is underway to test if senolytics decrease SARS-CoV-2 progression and morbidity in hospitalized older …
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multicenter, randomized, adaptive allocation clinical trial.
Silva M, Wacker DA, Driver BE, Staugaitis A, Niedernhofer LJ, Schmidt EL, Kirkland JL, Tchkonia T, Evans T, Serrano CH, Ventz S, Koopmeiners JS, Puskarich MA; STOP-Sepsis Investigators. Silva M, et al. Trials. 2024 Oct 21;25(1):698. doi: 10.1186/s13063-024-08474-2. Trials. 2024. PMID: 39434114 Free PMC article.
The prevalence of these cells increases with age and emerging data implicate senescence-associated maladaptive signaling as a potential contributor to sepsis and septic shock. The senolytic drug fisetin promotes clearance of senescent cells and is hypothesized to mi …
The prevalence of these cells increases with age and emerging data implicate senescence-associated maladaptive signaling as a potential cont …
Strategies for late phase preclinical and early clinical trials of senolytics.
Wissler Gerdes EO, Misra A, Netto JME, Tchkonia T, Kirkland JL. Wissler Gerdes EO, et al. Mech Ageing Dev. 2021 Dec;200:111591. doi: 10.1016/j.mad.2021.111591. Epub 2021 Oct 23. Mech Ageing Dev. 2021. PMID: 34699859 Free PMC article. Review.
Clinical trials with other senolytics, including the flavonoid Fisetin and BCL-xL inhibitors, are underway. These results from preclinical and early clinical trials illustrate the potential of senolytics to alleviate age-related dysfunction and diseases. ...P …
Clinical trials with other senolytics, including the flavonoid Fisetin and BCL-xL inhibitors, are underway. These results from …
Discovery, development, and future application of senolytics: theories and predictions.
Wissler Gerdes EO, Zhu Y, Tchkonia T, Kirkland JL. Wissler Gerdes EO, et al. FEBS J. 2020 Jun;287(12):2418-2427. doi: 10.1111/febs.15264. Epub 2020 Mar 17. FEBS J. 2020. PMID: 32112672 Free PMC article. Review.
Senescent cells do not replicate, can release factors that cause tissue dysfunction, and yet remain viable. The discovery of senolytic drugs, agents that selectively eliminate senescent cells, created a new route for alleviating age-related dysfunction and diseases. As ant …
Senescent cells do not replicate, can release factors that cause tissue dysfunction, and yet remain viable. The discovery of senolytic …
Senolytics as Modulators of Critical Signaling Pathways: a Promising Strategy to Combat Brain Aging and Neurodegenerative Disorders.
Singh I, Singh AK. Singh I, et al. Mol Neurobiol. 2025 Dec 6;63(1):261. doi: 10.1007/s12035-025-05504-1. Mol Neurobiol. 2025. PMID: 41351658 Free PMC article. Review.
These senescent cells cause neuroinflammation and dysfunction of the neuronal microenvironment by transmitting senescent phenotypes to neighboring healthy cells. Senolytics have become a viable treatment option to reduce the effects of brain aging since they specifically t …
These senescent cells cause neuroinflammation and dysfunction of the neuronal microenvironment by transmitting senescent phenotypes to neigh …
Polyphenols and Diets as Current and Potential Nutrition Senotherapeutics in Alzheimer's Disease: Findings from Clinical Trials.
Chen X, Walton K, Brodaty H, Chalton K. Chen X, et al. J Alzheimers Dis. 2024;101(s1):S479-S501. doi: 10.3233/JAD-231222. J Alzheimers Dis. 2024. PMID: 38875032 Review.
Promising results with neuroprotective effects of senotherapeutic agents such as quercetin, resveratrol, Epigallocatechin-gallate, curcumin and fisetin were reported from preclinical studies. However, in-human trials remain limited, and findings were inconclusive. ...
Promising results with neuroprotective effects of senotherapeutic agents such as quercetin, resveratrol, Epigallocatechin-gallate, curcumin …
eIF3a R803K mutation mediates chemotherapy resistance by inducing cellular senescence in small cell lung cancer.
Chen YX, Wang CJ, Xiao DS, He BM, Li M, Yi XP, Zhang W, Yin JY, Liu ZQ. Chen YX, et al. Pharmacol Res. 2021 Dec;174:105934. doi: 10.1016/j.phrs.2021.105934. Epub 2021 Oct 11. Pharmacol Res. 2021. PMID: 34648968 Clinical Trial.
Further studies revealed that the eIF3A R803K mutation promotes cellular senescence. In addition, fisetin showed a synergistic effect with chemotherapy in eIF3A R803K mutant cells. These results suggest that the eIF3A R803K somatic mutation has the potential to predict che …
Further studies revealed that the eIF3A R803K mutation promotes cellular senescence. In addition, fisetin showed a synergistic effect …
Pharmacological targeting of the senescence-associated secretory phenotype in atherosclerosis: therapeutic potential of senolytics and senomorphics.
Manni E, Al-Kuraishy HM, Fawzy MN, Batiha GE. Manni E, et al. Naunyn Schmiedebergs Arch Pharmacol. 2026 May 14. doi: 10.1007/s00210-026-05416-4. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2026. PMID: 42133066 Review.
Two complementary pharmacological strategies have emerged. Senolytics (dasatinib combined with quercetin, fisetin, and lanatoside C) specifically eradicate senescent cells by inhibiting anti-apoptotic pathways (BCL-2, PI3K/AKT, and HSP90). ...This review offers an e …
Two complementary pharmacological strategies have emerged. Senolytics (dasatinib combined with quercetin, fisetin, and lanatos …
Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline.
Alameen AAM, Al-Kuraishy HM, Fawzy MN, Batiha GE. Alameen AAM, et al. Naunyn Schmiedebergs Arch Pharmacol. 2026 Apr 23. doi: 10.1007/s00210-026-05309-6. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2026. PMID: 42024235 Review.
Preliminary human studies involving FOXO4-axis modulators, such as high-dose fisetin, show a reduction in the senescence-associated secretory phenotype (SASP) and enhancements in cognitive and physical measures among older adults. These findings collectively identify the F …
Preliminary human studies involving FOXO4-axis modulators, such as high-dose fisetin, show a reduction in the senescence-associated s …